This company has been acquired
COEP Stock Overview
Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops cell therapy platforms for patients with cancer.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Coeptis Therapeutics Holdings, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.35 |
| 52 Week High | US$14.00 |
| 52 Week Low | US$1.65 |
| Beta | 0 |
| 1 Month Change | 42.55% |
| 3 Month Change | 41.95% |
| 1 Year Change | -30.93% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 3.08% |
Recent News & Updates
Recent updates
Shareholder Returns
| COEP | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 52.3% | -2.2% | -0.9% |
| 1Y | -30.9% | 13.8% | 25.0% |
Return vs Industry: COEP underperformed the US Pharmaceuticals industry which returned 8.9% over the past year.
Return vs Market: COEP underperformed the US Market which returned -21.7% over the past year.
Price Volatility
| COEP volatility | |
|---|---|
| COEP Average Weekly Movement | 13.4% |
| Pharmaceuticals Industry Average Movement | 9.3% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: COEP's share price has been volatile over the past 3 months.
Volatility Over Time: COEP's weekly volatility has decreased from 24% to 13% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 5 | Dave Mehalick | coeptistx.com |
Coeptis Therapeutics, Inc., a biopharmaceutical company, develops and commercializes generic and branded pharmaceutical products and cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a Vy-Gen drug product for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; and CD38-Diagnostic, an in vitro screening tool to provide the ability to pre-determine which cancer patients are most likely to benefit from targeted anti-CD38 monoclonal antibodies therapies. The company has collaboration with Statera BioPharma to develop and commercialize STAT-201 for Crohn’s disease; and Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson’s Disease.
Coeptis Therapeutics Holdings, Inc. Fundamentals Summary
| COEP fundamental statistics | |
|---|---|
| Market cap | US$171.54m |
| Earnings (TTM) | -US$37.77m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-4.5x
P/E RatioIs COEP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| COEP income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$37.77m |
| Earnings | -US$37.77m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.74 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 185.0% |
How did COEP perform over the long term?
See historical performance and comparison